Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Heparin, Baxter, the FDA and China

publication date: Mar 5, 2008

The FDA and Baxter International announced today that a heparin-like molecule found in Baxter’s supplies of heparin may be the culprit in the recent wave of heparin-caused side effects. Baxter, which produces half of the US supply of heparin, has recalled all of its heparin products. Between 5% and 20% of the raw material sampled seemed to be contaminated. The brouhaha has caused a call for more and better FDA inspections of foreign-sourced drugs and APIs, but that may be difficult to achieve.  More details...

Stock Symbol: (NYSE: BAX)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital